Results 251 to 260 of about 892,099 (304)

Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.

JAMA Oncol
Chen C, Liang X, Peng Z, Zou Y, He H, Zhang X, He Y, Wu S.   +7 more
europepmc   +1 more source

Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node-Targeting and Augments mRNA Vaccine Efficacy. [PDF]

Adv Sci (Weinh)
Ha M, Kim J, Kim S, Naidu GS, Cho S, Yong SB.   +5 more
europepmc   +1 more source

CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer. [PDF]

J Immunother Cancer
Muneer A, Showkatian E, Kitsel Y, Saad MB, Sujit SJ, Soto F, Shroff GS, Faiz SA, Ghanbar MI, Ismail SM, Vokes NI, Cascone T, Le X, Zhang J, Byers LA, Jaffray D, Chang JY, Liao Z, Naing A, Gibbons DL, Vaporciyan AA, Heymach JV, Suresh K, Altan M, Sheshadri A, Wu J.   +25 more
europepmc   +1 more source

Current Knowledge of Immune Checkpoint Inhibitor-Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management. [PDF]

Cancer Med
Dai Y, Yang W, Sun Z, Wu L, Shao K, Wu D.   +5 more
europepmc   +1 more source

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis

Clinical Medicine Insights: Endocrinology and Diabetes, 2015
Moeber Mahzari, Dora Liu, Amel Arnaout, Heather Lochnan   +3 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Checkpoint inhibitors

Hematology, 2023
Abstract Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. These medications commonly cause immune-related adverse effects due to activated adaptive and innate immune cells, autoantibody production, and/or cytokine dysregulation.
openaire   +2 more sources